Novartis gets EU nod for Jakavi cancer drug; Sun's Caraco gets FDA clearance for U.S. plants;

 @FiercePharma: AstraZeneca's gain is Roche's loss: Stock down 1% after $AZN woos away Pascal Soriot for CEO job. More | Follow @FiercePharma

> Novartis ($NVS) won approval from European regulators for its myelofibrosis treatment Jakavi, the first drug approved for the rare blood cancer. Report

> Sun Pharmaceuticals got the go-ahead from FDA to restart manufacturing operations at a U.S. subsidiary's plant and packaging facilties in Detroit and Wixom, MI. Report

> UBS downgraded GlaxoSmithKline ($GSK) to "neutral" from "buy," saying it doesn't expect GSK stock to continue outperforming its peers. Report

> India's Cipla is scouting Mumbai to buy office space for a headquarters relocation, The Economic Times reports. Report

> Express Scripts persuaded a U.S. judge to dismiss most of the antitrust claims lodged against its $29 billion buyout of Medco Health Solutions, by drugstore chains and a pharmacy association. Report

Medical Device News

@FierceMedDev: Moving on from the Duet recall, Covidien gets a 510(k) for its next-gen surgical stapler. News | Follow @FierceMedDev

 @MarkHFierce: Stent use can help certain patients more than medical therapy if used on the early side. Release | Follow @MarkHFierce

 @DamianFierce: Joining other big shots in the device game, Medtronic has opened an R&D center in China. Report | Follow @DamianFierce

> Sequenom expands prenatal diagnostic with overseas deals. Story

> Shake-up at Roche puts Diggelmann in charge of diagnostics. News

Biotech News

 @FierceBiotech: Special report: The Alzheimer's pipeline... What's next? Report | Follow @FierceBiotech

 @JohnCFierce: Resverlogix touts positive PhIIb atherosclerosis data, sets sights on PhIII deal. More | Follow @JohnCFierce

 @RyanMFierce: What changes will Roche vet Pascal Soriot make as CEO of AstraZeneca? More | Follow @RyanMFierce

> Alnylam reaps $29M harvest in new ag bio deal with Monsanto. News

> Analysis: Where will Pascal Soriot take AstraZeneca now? More

> FDA OK for HIV pill Quad sets up potential confrontation over Gilead's price. Article

Biotech Research News

> Acorda's drug treats nerve damage-related ED in preclinical test. Article

> Novira raises $23M for hepatitis B/HIV drug work. News

> Genentech, U. Minnesota scientists discover new colon cancer red flags. Story

> Johns Hopkins team turning blood cells into stem cells. More

> Melanoma stem cells may carry provocative drug target. Item

Pharma Manufacturing News

> Drugmaker EirGen thinks plan to put waste station nearby stinks. More

> Sun says FDA clears plants where Marshalls seized products in 2009. News

> CSL, whose vaccine was tied to convulsions, gets FDA closeout letter. Story

> Hospira commits to 200 jobs, $85M investment, at troubled plant. Report

And Finally... Cancer patients need treatment for emotional and psychological distress, too. Report

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.